These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32220540)

  • 1. MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.
    Zhang L; Rastgoo N; Wu J; Zhang M; Pourabdollah M; Zacksenhaus E; Chen Y; Chang H
    Cancer Lett; 2020 Jun; 480():29-38. PubMed ID: 32220540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
    Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
    Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
    Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
    Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
    [No Abstract]   [Full Text] [Related]  

  • 7. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
    Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
    J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.
    Mizuno S; Hanamura I; Ota A; Karnan S; Narita T; Ri M; Mizutani M; Goto M; Gotou M; Tsunekawa N; Shikami M; Iida S; Hosokawa Y; Miwa H; Ueda R; Nitta M; Takami A
    Int J Hematol; 2015 Nov; 102(5):569-78. PubMed ID: 26341959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
    Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
    Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Wu H; Liu C; Yang Q; Xin C; Du J; Sun F; Zhou L
    Autophagy; 2020 Apr; 16(4):683-697. PubMed ID: 31242129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
    Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
    Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
    Jarauta V; Jaime P; Gonzalo O; de Miguel D; Ramírez-Labrada A; Martínez-Lostao L; Anel A; Pardo J; Marzo I; Naval J
    Cancer Lett; 2016 Nov; 382(1):1-10. PubMed ID: 27565383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
    Nikesitch N; Rebeiro P; Ho LL; Pothula S; Wang XM; Khong T; Quek H; Spencer A; Lee CS; Roberts TL; Ling SCW
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943972
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
    Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.
    Roy M; Liang L; Xiao X; Peng Y; Luo Y; Zhou W; Zhang J; Qiu L; Zhang S; Liu F; Ye M; Zhou W; Liu J
    Theranostics; 2016; 6(12):2209-2224. PubMed ID: 27924158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.